To create an optimized E-visit by engaging with member stakeholders; and implement a randomized study in select facilities with a revised E-visit that follows a personalized-medicine approach and compares it to the recently activated E-visit.
In 2012, the US Preventive Services Task Force (USPSTF) recommended against PSA-based screening for prostate cancer in men of all ages. Following this change, screening declined yet the complete impact on clinical presentation is not well defined in the screen-eligible…
Prostate cancer screening is associated with low specificity, unnecessary biopsies, and overdiagnosis. We have previously shown that the Stockholm-3 model (S3M) can reduce biopsies compared with using prostate-specific antigen (PSA) ≥3ng/ml as an indication for biopsy. Urologists in today's current…
Much of the controversy surrounding prostate cancer screening is due to the poor predictive value of PSA blood tests and the risks attendant to over-diagnosis. This project aims to develop a risk calculator that uses clinical variables to determine the…
A 17-gene biopsy-based reverse transcription polymerase chain reaction assay, which provides a Genomic Prostate Score (GPS-scale 0-100), has been validated as an independent predictor of adverse pathology and biochemical recurrence after radical prostatectomy (RP) in men with low- and intermediate-risk…
Division of Research
2000 Broadway
Oakland, CA 94612
(510) 891-3400
Privacy Policy | Terms and Conditions
Follow us on these external social media sites that will open in a new browser window.
© 2023 Kaiser Permanente Division of Research